Real-Time News FIRE FAST SIP Calculators

Easy-to-understand Financial Insights
that build Wealth.

Explore Dzambhala NodeX

DRREDDY

NSE: DRREDDY | BSE: 500124

Latest on DRREDDY

Dr. Reddy's Secures Interim Stay on ₹1,000 Cr Tax Reassessment Linked to Merger August 26, 2025 | 4:58 p.m. IST
Dr. Reddy's Issues 4,160 Equity Shares Under Employee Stock Options, Boosting Capital to ₹83.46 Cr August 20, 2025 | 11:52 a.m. IST
Dr. Reddy's Receives USFDA Establishment Inspection Report Classifying Outcome as 'Voluntary Action Indicated' August 8, 2025 | 4:20 p.m. IST
Dr. Reddy's Dissolves Wholly Owned Subsidiary Imperial Owners and Land Possessions Following NCLT Approval August 8, 2025 | 11:46 a.m. IST
Dr. Reddy's Reports Q1FY26 Revenue of ₹8,545 Cr With 11% Year-on-Year Growth Despite Pricing Pressures July 29, 2025 | 11:17 p.m. IST
Dr. Reddy's Invests ₹565.41 Cr in Russian Subsidiary to Secure 45.19% Equity Stake July 25, 2025 | 7:43 p.m. IST
Dr. Reddy's Re-appoints G V Prasad as Co-Chairman and Managing Director for 5-Year Term Starting January 30, 2026 July 24, 2025 | 9:50 p.m. IST
Dr. Reddy's Appoints Makarand M. Joshi & Co. As Secretarial Auditors for Five-Year Term Starting April 2025 July 24, 2025 | 9:49 p.m. IST
Dr. Reddy's Laboratories Declares ₹8 Dividend Per Share at 41st AGM July 24, 2025 | 9:39 p.m. IST
Dr. Reddy's Laboratories Declares ₹8 Dividend at 41st AGM, Reappoints G V Prasad as Co-Chairman July 24, 2025 | 9:38 p.m. IST
Dr. Reddy's Laboratories Publishes Unaudited Financial Results for Q1 FY 2025-26 July 24, 2025 | 4:00 p.m. IST
Dr. Reddy's Laboratories Reports Q1 FY26 Revenue of ₹85,452 Lakhs and Net Profit of ₹14,096 Lakhs July 23, 2025 | 5:11 p.m. IST
Dr. Reddy's Laboratories Reports Q1 FY26 Revenues of ₹8,545 Cr and Net Profit of ₹1,418 Cr July 23, 2025 | 5:02 p.m. IST
Dr. Reddy's Proposes Appointment of Deloitte as Statutory Auditors for FY 2026-27 July 23, 2025 | 5:02 p.m. IST
Dr. Reddy's Laboratories Reports Q1 FY26 Revenue Growth of 11.3% to ₹85,452 Lakhs Despite Net Profit Dip July 23, 2025 | 4:39 p.m. IST
Dr. Reddy's Receives USFDA Inspection Report Classifying Outcome as 'Voluntary Action Indicated' July 22, 2025 | 8:37 p.m. IST
Dr. Reddy's Opens Special Window for Share Transfer Requests from July 7, 2025, to January 6, 2026 July 22, 2025 | 7:28 p.m. IST
Dr. Reddy's Receives USFDA Establishment Inspection Report, Classified as Voluntary Action Indicated July 21, 2025 | 8:28 p.m. IST
Dr. Reddy's Receives Form 483 With 7 Observations From USFDA After Srikakulam Facility Inspection July 18, 2025 | 5:48 p.m. IST
Dr. Reddy's Laboratories Faces ₹2395.81 Cr Tax Reassessment Notice Linked to 2019-20 Returns April 5, 2025 | 12:30 p.m. IST
Dr. Reddy's Completes Sale of Louisiana Manufacturing Subsidiary March 22, 2025 | 1:01 p.m. IST
Dr. Reddy's Laboratories To Approve FY 2024-25 Financial Results and Consider Final Dividend on May 9, 2025 March 21, 2025 | 8:48 p.m. IST
Dr. Reddy's Laboratories To Approve FY 2024-25 Financial Results And Discuss Final Dividend On May 9, 2025 March 21, 2025 | 8:26 p.m. IST
Dr. Reddy's Laboratories Reports Transmission of 56,02,495 Shares Among Promoters, No Change in Overall Shareholding March 20, 2025 | 4:13 p.m. IST
Dr. Reddy's Recalls Batch of Levetiracetam Injection Due to Mislabeling Risks March 13, 2025 | 5:17 p.m. IST
Dr. Reddy's Allots 11,250 Shares Under Employee Stock Options to Boost Talent Retention March 6, 2025 | 5:01 p.m. IST
Dr. Reddy's Receives ₹38.63 Lac Tax Demand Order with Penalty for Irregular Credit February 28, 2025 | 5:22 p.m. IST
Dr. Reddy's Receives USFDA Inspection Report Classifying Findings as 'Voluntary Action Indicated' for API Facility February 25, 2025 | 4:05 p.m. IST
Dr. Reddy's Allots 20,155 Equity Shares to Employees Under ESOP 2002 February 14, 2025 | 6:12 p.m. IST
Dr. Reddy's Laboratories Receives GST Tax Demand of ₹1.80 Cr With Penalty Over Cenvat Credit Irregularities February 12, 2025 | 5:04 p.m. IST
Dr. Reddy's Laboratories Hit With ₹184.36 Cr GST Penalty for Excess Refund Claims February 2, 2025 | 6:41 p.m. IST
Dr. Reddy's Reports Q3FY25 Earnings of ₹8,359 Cr, Achieving 16% YoY Revenue Growth and Highest-Ever EBITDA of ₹2,298 Cr January 29, 2025 | 8:34 p.m. IST
Dr. Reddy's Laboratories To Participate In Investor Conference In Hyderabad On February 5, 2025 January 29, 2025 | 4:42 p.m. IST
Dr. Reddy's Laboratories Files Q4 2024 Financial Results With SEC, Complying With Regulatory Standards January 24, 2025 | 1:42 p.m. IST
Dr. Reddy’s Laboratories Reports Unaudited Financial Results for Q3 FY 2024 January 24, 2025 | 1:31 p.m. IST
Dr. Reddy's Laboratories Reports Q3 Revenue of ₹8,358.6 Cr and Net Profit of ₹1,403.8 Cr, Completes Haleon Acquisition for ₹5,140.7 Cr January 24, 2025 | 1:20 p.m. IST
Dr. Reddy's Laboratories Shares Q3 2024 Earnings Call Audio, No Major Updates Disclosed January 24, 2025 | 9:09 a.m. IST
Dr. Reddy's Laboratories Reports Q3FY25 Revenue of ₹83,586 Million, Net Profit Rises 2% Year-on-Year January 23, 2025 | 5:33 p.m. IST
Dr. Reddy’s Laboratories Faces Antitrust Lawsuits Over Revlimid Patent Settlement Delays January 22, 2025 | 11:03 p.m. IST